gemfibrozil has been researched along with Cardiovascular Stroke in 32 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We conducted a double-blind trial comparing gemfibrozil (1200 mg per day) with placebo in 2531 men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1." | 9.09 | Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. ( Anderson, JW; Collins, D; Elam, MB; Faas, FH; Fye, CL; Linares, E; Robins, SJ; Rubins, HB; Schaefer, EJ; Schectman, G; Wilt, TJ; Wittes, J, 1999) |
| "The effects of gemfibrozil on haemostatic variables were studied in 43 survivors of myocardial infarction with serum triglycerides (TG) greater than or equal to 2 mmol/l 2 weeks prior to randomization." | 9.06 | Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. ( Andersen, P; Arnesen, H; Brataker, S; Seljeflot, I; Smith, P, 1990) |
| "02) reduction in the incidence of cardiac end points (myocardial infarction and cardiac death) with the use of gemfibrozil compared with the use of a placebo in dyslipidemic middle-aged men." | 9.06 | Reduction in Q wave myocardial infarctions with gemfibrozil in the Helsinki Heart Study. ( Frick, MH; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M; Romo, M, 1990) |
| "The effects of gemfibrozil on serum lipids and apolipoproteins were investigated in 60 male survivors of myocardial infarction (MI) (age range 29-48 years, mean 44)." | 9.05 | Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. ( Ehnholm, C; Kaukola, S; Mälkönen, M; Manninen, V, 1981) |
| "The purpose of the present study was to assess the effect of gemfibrozil on 12 independent coronary heart disease risk factors in patients with primary combined hyperlipidaemia." | 7.69 | Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia. ( Athyros, VG; Avramidis, MJ; Kontopoulos, AG; Papageorgiou, AA, 1995) |
| "Smoking and dyslipidemia are more potent risk factors for nonfatal MI in males who have the -344C allele of CYP11B2." | 6.69 | Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. ( Hautanen, A; Kayes, KM; Kupari, M; Manninen, V; Mänttäri, M; Rosenfeld, S; Tenkanen, L; Toivanen, P; White, PC, 1999) |
| " It is unclear if polymyositis was triggered by interaction of the statin with omeprazole and/or gemfibrozil, or if it developed secondary to long-term use of atorvastatin only." | 5.39 | Statin-associated polymyositis following omeprazole treatment. ( Flores, RM; Kanth, R; Shah, MS, 2013) |
| "We conducted a double-blind trial comparing gemfibrozil (1200 mg per day) with placebo in 2531 men with coronary heart disease, an HDL cholesterol level of 40 mg per deciliter (1." | 5.09 | Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. ( Anderson, JW; Collins, D; Elam, MB; Faas, FH; Fye, CL; Linares, E; Robins, SJ; Rubins, HB; Schaefer, EJ; Schectman, G; Wilt, TJ; Wittes, J, 1999) |
| "Relation of lipid levels at baseline and averaged during the first 18 months of gemfibrozil treatment with the combined incidence of nonfatal myocardial infarction and CHD death." | 5.09 | Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. ( Collins, D; Deedwania, PC; Hershman, JM; Kashyap, ML; McNamara, JR; Papademetriou, V; Robins, SJ; Rubins, HB; Schaefer, EJ; Wexler, LF; Wittes, JT, 2001) |
| " The study has the following 3 key objectives: to define the cost effectiveness of gemfibrozil in the prevention of coronary heart disease (CHD); to assess the net impact of gemfibrozil on total treatment costs for CHD; and to identify those patient groups for whom gemfibrozil therapy is most cost effective." | 5.06 | Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy. ( Fifer, SK; Sarma, S, 1990) |
| "The effects of gemfibrozil on haemostatic variables were studied in 43 survivors of myocardial infarction with serum triglycerides (TG) greater than or equal to 2 mmol/l 2 weeks prior to randomization." | 5.06 | Effects of gemfibrozil on lipids and haemostasis after myocardial infarction. ( Andersen, P; Arnesen, H; Brataker, S; Seljeflot, I; Smith, P, 1990) |
| "02) reduction in the incidence of cardiac end points (myocardial infarction and cardiac death) with the use of gemfibrozil compared with the use of a placebo in dyslipidemic middle-aged men." | 5.06 | Reduction in Q wave myocardial infarctions with gemfibrozil in the Helsinki Heart Study. ( Frick, MH; Heinonen, OP; Huttunen, JK; Koskinen, P; Manninen, V; Mänttäri, M; Romo, M, 1990) |
| "In the Helsinki Heart Study, a randomized five-year, double-blind trial, a 34% reduction in the incidence of coronary heart disease (CHD) was observed in dyslipidemic men treated with gemfibrozil." | 5.06 | Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. ( Elo, MO; Frick, MH; Haapa, K; Heinonen, OP; Heinsalmi, P; Helo, P; Huttunen, JK; Kaitaniemi, P; Koskinen, P; Manninen, V, 1988) |
| "The effects of gemfibrozil on serum lipids and apolipoproteins were investigated in 60 male survivors of myocardial infarction (MI) (age range 29-48 years, mean 44)." | 5.05 | Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. ( Ehnholm, C; Kaukola, S; Mälkönen, M; Manninen, V, 1981) |
| "(1) In primary prevention trials, pravastatin and lovastatin prevented myocardial infarction and had a positive risk-benefit ratio in men with LDL-cholesterol values exceeding 4." | 3.70 | Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention. ( , 1999) |
| "The purpose of the present study was to assess the effect of gemfibrozil on 12 independent coronary heart disease risk factors in patients with primary combined hyperlipidaemia." | 3.69 | Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia. ( Athyros, VG; Avramidis, MJ; Kontopoulos, AG; Papageorgiou, AA, 1995) |
| "Since dyslipidemia is common in diabetes and is associated with increased cardiovascular risk, we tested the hypothesis that Thr-54 is associated with increased cardiovascular risk in patients with diabetes." | 2.73 | Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT). ( Bloomfield, H; Brousseau, ME; Collins, D; Georgopoulos, A; O'Connor, JJ; Ordovas, JM; Robins, SJ; Schaefer, EJ, 2007) |
| "Smoking and dyslipidemia are more potent risk factors for nonfatal MI in males who have the -344C allele of CYP11B2." | 2.69 | Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. ( Hautanen, A; Kayes, KM; Kupari, M; Manninen, V; Mänttäri, M; Rosenfeld, S; Tenkanen, L; Toivanen, P; White, PC, 1999) |
| " A metaanalysis of ten trials has shown a 25% decrease in vascular events in the long-term, irrespective of age, gender, blood pressure blood glucose level, and dosage whether low (75 to 160 mg) or moderate (160 to 325 mg/day)." | 2.39 | [Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents]. ( Aumont, MC; Seknadji, P, 1996) |
| " It is unclear if polymyositis was triggered by interaction of the statin with omeprazole and/or gemfibrozil, or if it developed secondary to long-term use of atorvastatin only." | 1.39 | Statin-associated polymyositis following omeprazole treatment. ( Flores, RM; Kanth, R; Shah, MS, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (12.50) | 18.7374 |
| 1990's | 15 (46.88) | 18.2507 |
| 2000's | 9 (28.13) | 29.6817 |
| 2010's | 4 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kanth, R | 1 |
| Shah, MS | 1 |
| Flores, RM | 1 |
| Wang, D | 1 |
| Liu, B | 1 |
| Tao, W | 1 |
| Hao, Z | 1 |
| Liu, M | 1 |
| Jakob, T | 1 |
| Nordmann, AJ | 1 |
| Schandelmaier, S | 1 |
| Ferreira-González, I | 1 |
| Briel, M | 1 |
| Kar, S | 1 |
| Chockalingam, A | 1 |
| Corvol, JC | 1 |
| Bouzamondo, A | 1 |
| Sirol, M | 1 |
| Hulot, JS | 1 |
| Sanchez, P | 1 |
| Lechat, P | 1 |
| Kervinen, H | 1 |
| Huittinen, T | 1 |
| Vaarala, O | 1 |
| Leinonen, M | 1 |
| Saikku, P | 1 |
| Manninen, V | 8 |
| Mänttäri, M | 5 |
| Georgopoulos, A | 1 |
| Bloomfield, H | 1 |
| Collins, D | 4 |
| Brousseau, ME | 1 |
| Ordovas, JM | 1 |
| O'Connor, JJ | 1 |
| Robins, SJ | 5 |
| Schaefer, EJ | 4 |
| Nelson, JJ | 1 |
| Bloomfield, HE | 1 |
| Asztalos, BF | 1 |
| Mälkönen, M | 2 |
| Eisalo, A | 1 |
| Virtamo, J | 1 |
| Tuomilehto, J | 1 |
| Kuusisto, P | 1 |
| Kaukola, S | 1 |
| Ehnholm, C | 1 |
| Athyros, VG | 2 |
| Papageorgiou, AA | 2 |
| Avramidis, MJ | 1 |
| Kontopoulos, AG | 2 |
| Bucher, HC | 1 |
| Weinbacher, M | 1 |
| Gyr, K | 1 |
| Rubins, HB | 3 |
| Iwane, MK | 1 |
| Boden, WE | 1 |
| Elam, MB | 2 |
| Fye, CL | 2 |
| Gordon, DJ | 1 |
| Schectman, G | 2 |
| Wittes, JT | 2 |
| Aumont, MC | 1 |
| Seknadji, P | 1 |
| Oikarinen, L | 1 |
| Viitasalo, M | 1 |
| Rembold, CM | 1 |
| Anderson, JW | 1 |
| Faas, FH | 1 |
| Linares, E | 1 |
| Wilt, TJ | 1 |
| Wittes, J | 1 |
| Hautanen, A | 1 |
| Toivanen, P | 1 |
| Tenkanen, L | 1 |
| Kupari, M | 1 |
| Kayes, KM | 1 |
| Rosenfeld, S | 1 |
| White, PC | 1 |
| Damur, C | 1 |
| Steurer, J | 1 |
| Gaziano, JM | 1 |
| Papademetriou, V | 1 |
| Deedwania, PC | 1 |
| McNamara, JR | 1 |
| Kashyap, ML | 1 |
| Hershman, JM | 1 |
| Wexler, LF | 1 |
| Miller, M | 1 |
| Sprecher, DL | 1 |
| Naylor, CD | 1 |
| Chen, E | 1 |
| Strauss, B | 1 |
| Rybinski, EA | 1 |
| Sarma, S | 1 |
| Fifer, SK | 1 |
| Andersen, P | 1 |
| Smith, P | 1 |
| Seljeflot, I | 1 |
| Brataker, S | 1 |
| Arnesen, H | 1 |
| Romo, M | 2 |
| Koskinen, P | 2 |
| Huttunen, JK | 3 |
| Heinonen, OP | 3 |
| Frick, MH | 3 |
| Heinsalmi, P | 2 |
| Elo, MO | 1 |
| Haapa, K | 1 |
| Helo, P | 1 |
| Kaitaniemi, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Low Carbohydrate Diet Compared to Low Fat Diet in Reversing the Metabolic Syndrome Using NCEP ATP III Criteria; Randomized Clinical Trial[NCT04681924] | 94 participants (Actual) | Interventional | 2017-01-01 | Completed | |||
| CSP #363 - The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol[NCT00283335] | Phase 3 | 2,531 participants (Actual) | Interventional | 1991-06-30 | Completed | ||
| Treatment Study for Severe High-Density Lipoprotein Deficiency[NCT00458055] | 19 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for gemfibrozil and Cardiovascular Stroke
| Article | Year |
|---|---|
Fibrates for secondary prevention of cardiovascular disease and stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Bezafibrate; Cardiovascular Diseases; Caus | 2015 |
Fibrates for primary prevention of cardiovascular disease events.
Topics: Atorvastatin; Bezafibrate; Cardiovascular Diseases; Clofibric Acid; Fenofibrate; Gemfibrozil; Humans | 2016 |
Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic NSTEMI: a review of lipid management considerations.
Topics: Acute Kidney Injury; Aged, 80 and over; Coronary Artery Disease; Drug Therapy, Combination; Gemfibro | 2013 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; H | 2003 |
[Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents].
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Gemfibrozil; Humans; Hyp | 1996 |
Triglycerides and coronary risk.
Topics: Biomarkers; Coronary Disease; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agent | 1999 |
Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial.
Topics: Aged; Anticholesteremic Agents; Cholesterol, HDL; Confounding Factors, Epidemiologic; Coronary Disea | 2000 |
Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Drug Combinations; Female; Gemfibrozil | 2000 |
16 trials available for gemfibrozil and Cardiovascular Stroke
| Article | Year |
|---|---|
Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT).
Topics: Aged; Codon; Diabetes Mellitus; Dyslipidemias; Fatty Acid-Binding Proteins; Gemfibrozil; Genetic Pre | 2007 |
Gemfibrozil in the treatment of dyslipidaemia. A 5-year follow-up study.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clinical Trials as Topic; Follow | 1982 |
Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction.
Topics: Adult; Apolipoproteins; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Gemfibrozil; Hum | 1981 |
Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration.
Topics: Adult; Attitude of Health Personnel; Decision Making; Female; Gemfibrozil; Humans; Hypercholesterole | 1994 |
Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lip
Topics: Adult; Aged; Cause of Death; Cholesterol, HDL; Cholesterol, LDL; Clinical Protocols; Coronary Diseas | 1993 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Follow-Up Studies; | 1999 |
Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction.
Topics: Adult; Aldosterone; Alleles; Baroreflex; Case-Control Studies; Cholesterol, HDL; Cholesterol, LDL; C | 1999 |
[Do physicians interpret therapy outcome differently than students?].
Topics: Angina Pectoris; Attitude of Health Personnel; Education, Medical; Education, Medical, Continuing; E | 2000 |
Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Gemfibrozil; Humans; Hypo | 2001 |
Statin-fibrate combinations in patients with combined hyperlipedemia.
Topics: Clofibric Acid; Coronary Disease; Drug Therapy, Combination; Fibric Acids; Follow-Up Studies; Gemfib | 2001 |
Measured enthusiasm: does the method of reporting trial results alter perceptions of therapeutic effectiveness?
Topics: Adult; Attitude of Health Personnel; Clinical Trials as Topic; Data Interpretation, Statistical; Gem | 1992 |
Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy.
Topics: Adult; Coronary Disease; Cost-Benefit Analysis; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle A | 1990 |
Effects of gemfibrozil on lipids and haemostasis after myocardial infarction.
Topics: Aged; Body Mass Index; Double-Blind Method; Female; Fibrinolysis; Gemfibrozil; Hemostasis; Humans; H | 1990 |
Reduction in Q wave myocardial infarctions with gemfibrozil in the Helsinki Heart Study.
Topics: Creatine Kinase; Double-Blind Method; Electrocardiography; Gemfibrozil; Humans; Hypercholesterolemia | 1990 |
Helsinki Heart Study. New perspectives in the prevention of coronary heart disease.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Double-Blind | 1988 |
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
Topics: Adult; Coronary Disease; Double-Blind Method; Finland; Gemfibrozil; Humans; Hypolipidemic Agents; Li | 1988 |
8 other studies available for gemfibrozil and Cardiovascular Stroke
| Article | Year |
|---|---|
Statin-associated polymyositis following omeprazole treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Interactions; Esophagitis; Gemfibrozil; Heptanoic Acids | 2013 |
Antibodies to human heat shock protein 60, hypertension and dyslipidemia. A study of joint effects on coronary risk.
Topics: Antibodies; Chaperonin 60; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypertension; Hyp | 2003 |
Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Apolipoproteins B; Cardiovascular Diseases; Ch | 2008 |
Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia.
Topics: Coronary Disease; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Lipids; Male; Midd | 1995 |
QT dispersion as a risk factor for sudden cardiac death and fatal myocardial infarction in a coronary risk population.
Topics: Adult; Case-Control Studies; Death, Sudden, Cardiac; Electrocardiography; Gemfibrozil; Heart Rate; H | 1997 |
Gemfibrozil to prevent myocardial infarction.
Topics: Cholesterol, LDL; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Myocardial Infarc | 1998 |
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
Topics: Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; F | 1999 |
The cholesterol controversy.
Topics: Gemfibrozil; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction | 1992 |